We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.2%
2 Industrials 0.08%
3 Consumer Staples 0.05%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBLA
226
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
$1.36M 0.05%
+14
New +$1.58M
ATYR
227
aTyr Pharma
ATYR
$48.2M
$1.34M 0.05%
300,000
-100,000
-25% -$470K
RUBY
228
DELISTED
Rubius Therapeutics, Inc
RUBY
$1.33M 0.04%
+50,000
New +$730K
AUPH icon
229
CALL
Aurinia Pharmaceuticals
AUPH
$1.87B
$1.3M 0.04%
100,000
– –
MITO
230
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$1.24M 0.04%
788,014
+750,417
+1,996% +$1.29M
EYPT icon
231
EyePoint Inc
EYPT
$1.04B
$1.22M 0.04%
+120,135
New +$1.35M
TDOC icon
232
PUT
Teladoc Health
TDOC
$1.21B
$1.18M 0.04%
+6,500
New +$1.51M
TRAW icon
233
Traws Pharma
TRAW
$7.18M
$1.14M 0.04%
+3,054
New +$1.15M
CRIS icon
234
CALL
Curis
CRIS
$10M
$1.13M 0.04%
250
-1,031
-80% -$4.31M
BCLI
235
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.12M 0.04%
+19,547
New +$1.48M
GMDA
236
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.1M 0.04%
136,142
-23,858
-15% -$219K
KRRO icon
237
PUT
Korro Bio
KRRO
$155M
$958K 0.03%
2,016
+298
+17% +$579K
KNSA icon
238
Kiniksa Pharmaceuticals
KNSA
$5.73B
$949K 0.03%
51,273
-50,000
-49% -$1.02M
SNDX icon
239
Syndax Pharmaceuticals
SNDX
$1.7B
$914K 0.03%
40,913
-100,000
-71% -$2.26M
ACIU icon
240
AC Immune
ACIU
$226M
$911K 0.03%
+119,803
New +$855K
CYCN icon
241
Cyclerion Therapeutics
CYCN
$15.1M
$836K 0.03%
+15,000
New +$1.13M
PSTX
242
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$820K 0.03%
85,837
-165,000
-66% -$1.62M
ICPT
243
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$808K 0.03%
+35,000
New +$976K
BLSA
244
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$794K 0.03%
75,100
+75,000
+75,000% +$847K
CEMI
245
DELISTED
Chembio diagnostics, Inc.
CEMI
$769K 0.03%
219,109
– –
FLACU
246
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$766K 0.03%
+75,000
New +$799K
CLOV icon
247
Clover Health Investments
CLOV
$2.28B
$757K 0.03%
100,000
– –
SYRS
248
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$748K 0.03%
10,000
– –
IRD
249
Opus Genetics
IRD
$301M
$693K 0.02%
+119,551
New +$1.11M
GRI
250
GRI Bio
GRI
$2.55M
– –
0
– –
8 9
10
11 12

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.